Badania kliniczne prowadzone w ośrodku Instytut Hematologii I Transfuzjologii (Ul Indiry Gandhi 14, Warszawa), które rekrutują lub wkrótce zaczną rekrutację. Dane pochodzą z rejestrów badań.
44 badania: 40 rekrutuje, 4 wkrótce zaczną.
Ośrodek niezweryfikowany
Instytut Hematologii I Transfuzjologii
Ul Indiry Gandhi 14
Warszawa
Otwórz w Mapach Google · OpenStreetMap
Ośrodek niezweryfikowany. Nazwa, adres i lista badań pochodzą z publicznych rejestrów badań klinicznych (CTIS, ClinicalTrials.gov). Ośrodek nie potwierdził tych danych z nami. Przed wizytą zadzwoń do nas, a nasz doradca sprawdzi aktualne informacje.
Mapa: © autorzy OpenStreetMap
Wpisz słowo, żeby przeszukać wszystkie 44 badania.
Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
+14A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
+19A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple…
+7A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
+15HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed…
+13Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
+10A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A
+4A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
MRD registry and multicenter, randomized controlled pragmatic trial of standard intensity versus reduced intensity consolidation treatment in MRD-negative patients with AML or…
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
+6A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
+12L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
+12Phase 1 trial of trametinib and gilteritinib for the treatment of relapsed or refractory acute leukemia patients
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
+12Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma…
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
+11A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
+2Study of Olverembatinib (HQP1351) in Patients With CML-CP
+8A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leukemia
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing…
+8A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well…
+17A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory…
+21Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
+6Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.